Sclerostin antibody crystals and formulations thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/22
A61K-039/395
A61K-039/00
출원번호
US-0006010
(2012-03-23)
등록번호
US-9145457
(2015-09-29)
국제출원번호
PCT/US2012/030364
(2012-03-23)
§371/§102 date
20131230
(20131230)
국제공개번호
WO2012/135035
(2012-10-04)
발명자
/ 주소
Clogston, Christi L.
Christian, Twinkle R.
Osslund, Timothy David
Freeman, Elisabeth
출원인 / 주소
AMGEN INC.
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
0인용 특허 :
56
초록
Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
대표청구항▼
1. A crystal of an anti-sclerostin IgG antibody comprising two mature light chains each comprised of SEQ ID NO: 13 and two mature heavy chains each comprised of SEQ ID NO: 15, wherein said crystals have a length of up to 500 μm and a shape selected from the group consisting of ellipsoids, rods and n
1. A crystal of an anti-sclerostin IgG antibody comprising two mature light chains each comprised of SEQ ID NO: 13 and two mature heavy chains each comprised of SEQ ID NO: 15, wherein said crystals have a length of up to 500 μm and a shape selected from the group consisting of ellipsoids, rods and needles or mixtures thereof. 2. A sterile formulation comprising the crystal of claim 1. 3. The formulation of claim 2, wherein the crystal comprises a salt selected from the group consisting of sodium dihydrogen phosphate, di-potassium hydrogen phosphate, sodium chloride, ammonium sulfate, potassium sodium tartrate tetrahydrate, tacsimate, sodium citrate dihydrate, sodium acetate trihydrate, di-ammonium tartrate, sodium malonate, acetate, calcium acetate, cacodylate, CHES, lithium sulfate, magnesium chloride, zinc acetate, cesium chloride, ammonium phosphate, sodium phosphase, potassium phosphate, sodium fluoride, potassium iodide, sodium idodide, ammonium iodide, sodium thiocyanate, potassium thiocyanate, sodium formate, potassium formate and ammonium formate. 4. The formulation of claim 2, that is a lyophilized formulation. 5. The formulation of claim 2, that is a liquid formulation. 6. The formulation of claim 5, comprising a concentration of at least about 100 mg of said antibody per ml of formulation. 7. The formulation of claim 5, comprising at least about 140 mg of antibody dispersed in 1.5 ml or less of liquid. 8. The formulation of claim 7 that is injectable through a syringe having a 20 Gauge needle or finer using a clinically acceptable amount of force. 9. The formulation of claim 2, that retains at least 50% of the in vivo activity, when given at the same dose and in the same manner, of a liquid formulation of said antibody that has not been crystallized. 10. The formulation of claim 7, that, when administered to a mammalian subject, mediates an increase in bone mineral density that is at least about 70% of the level of bone mineral density increase mediated by a liquid formulation of said antibody that has not been crystallized, wherein the formulation and the liquid formulation of the antibody that has not been crystallized is administered to the subject at the same dose and in the same manner. 11. A container comprising at least 50 mg of the antibody crystal of claim 1 for suspension in a volume of 0.5-2 mL. 12. A container comprising the formulation of claim 2. 13. A method of resuspending the formulation of claim 4, comprising contacting the formulation with about 0.5-2 mL of a sterile suspension vehicle. 14. A method of making a crystal of an anti-sclerostin IgG antibody comprising two mature light chains each comprised of SEQ ID NO: 13 and two mature heavy chains each comprised of SEQ ID NO: 15, wherein said crystals have a length of up to 500 μm and a shape selected from the group consisting of ellipsoids, rods and needles or mixtures thereof, the method comprising combining a solution of the antibody with a crystallization reagent comprising a salt selected from the group consisting of sodium dihydrogen phosphate, di-potassium hydrogen phosphate, sodium chloride, ammonium sulfate, ammonium acetate, potassium sodium tartrate tetrahydrate, tacsimate, sodium citrate dihydrate, sodium acetate trihydrate, di-ammonium tartrate, sodium malonate, acetate, calcium acetate, cacodylate, CHES, lithium sulfate, lithium acetate dihydrate, magnesium chloride, magnesium acetate tetrahydrate, magnesium formate, magnesium nitrate, magnesium sulfate, zinc acetate, zinc chloride, zinc sulfate, cesium chloride, ammonium phosphate, sodium phosphase, potassium phosphate, sodium fluoride, potassium iodide, sodium idodide, ammonium iodide, sodium thiocyanate, potassium thiocyanate, sodium formate, potassium formate and ammonium formate, optionally at pH of about 6 to about 8, such that a crystal is formed. 15. The method of claim 14, wherein the concentration of the salt is from about 0.1 M to about 10 M. 16. A method of making a crystal of an anti-sclerostin IgG antibody comprising two mature light chains each comprised of SEQ ID NO: 13 and two mature heavy chains each comprised of SEQ ID NO: 15, wherein said crystals have a length of up to 500 μm and a shape selected from the group consisting of ellipsoids, rods and needles or mixtures thereof, the method comprising combining a solution of the antibody with a crystallization reagent comprising succinic acid, PEG-1000, PEG-8000 or isopropanol such that a crystal is formed. 17. The method of claim 16, wherein the crystallization reagent comprises (a) from about 0.1 M to about 5 M succinic acid, from about 0.1 M to about 5 M HEPES and from about 0.1% (w/v) to about 60% (w/v) polyethylene glycol monomethyl ether 2000; (b) from about 1% (w/v) to about 50% (w/v) PEG-8000, from about 0.05 M to about 5 M imidazole and from about 0.1 M to about 5 M calcium acetate; (c) from about 10% to about 80% (w/v) PEG-1000, from about 0.05 M to about 5 M sodium/potassium phosphate and from about 0.05 M to about 5 M sodium chloride; (d) from about 1% (w/v) to about 20% (w/v) PEG-8000, from about 0.05 M to about 5 M cacodylate, from about 0.1 M to about 2 M calcium acetate, and from about 10% to about 30% (w/v) glycerol; or (e) from about 10% to about 30% isopropanol and from about 0.1 M to about 2 M sodium/potassium phosphate. 18. An antibody crystal produced by the method of claim 14. 19. A method of increasing bone mineral density, treating a disorder associated with decreased bone density, treating a bone-related disorder, or improving outcomes in a procedure, replacement, graft, surgery or repair in a mammalian subject comprising administering the formulation of claim 2 in an amount effective to increase bone mineral density in the subject. 20. An antibody crystal produced by the method of claim 16.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (56)
Btzow Ralf (Helsinki CA FIX) Ruoslahti Erkki (Rancho Santa Fe CA), 60 kDa transforming growth factor-b
상세보기
Brunkow, Mary E.; Galas, David J.; Kovacevich, Brian; Mulligan, John T.; Paeper, Bryan W.; Van Ness, Jeffrey; Winkler, David G., Antibodies associated with alterations in bone density.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan W; Van Ness, Jeffrey; Winkler, David G, Antibodies associated with alterations in bone density.
Dan Michael D.,CAX ; Maiti Pradip K.,CAX ; Kaplan Howard A.,CAX, Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers.
Brunkow, Mary E; Galas, David J; Kovacevich, Brian; Mulligan, John T; Paeper, Bryan; Van Ness, Jeffrey; Winkler, David G, Compositions and methods for increasing bone mineralization.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Compositions and methods for increasing bone mineralization.
Shenoy, Bhami; Govardhan, Chandrika P.; Yang, Mark X.; Margolin, Alexey L., Crystals of whole antibodies and fragments thereof and methods for making and using them.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Margolis David J. (Philadelphia PA), Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures.
Dasch James R. (Palo Alto CA) Pace ; III Doran R. (San Francisco CA) Waegell Wendy O. (Mountain View CA), Monoclonal antibodies which bind both transforming growth factors bb<.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Polypeptides associated with alterations in bone density.
Tsuchiya Masayuki,GB3 ; Sato Koh,GB3 ; Bendig Mary Margaret,GB3 ; Jones Steven Tarran,GB3 ; Saldanha Jose William,GB3, Reshaped human to human interleukin-6 receptor.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.